Table 1 Baseline characteristics of the patients examined, grouped based on randomised treatment
From: Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial
BDP/F 400/24 μg/day (N = 206) | FP/S 500/100 μg/day (N = 216) | ||
|---|---|---|---|
Age (years) | 44 (13) | 44 (13) | |
Gender | Male | 69 (33.5%) | 77 (35.6%) |
Female | 137 (66.5%) | 139 (64.4%) | |
BMI (kg/m2) | 27.1 (5.1) | 27.0 (5.2) | |
Device used before screening | pMDI | 12.6% | 12.6% |
DPI | 87.4% | 87.4% | |
Years from asthma diagnosis | 11 (10) | 13 (11) | |
FEV1, L | 2.9 (0.9) | 3.0 (0.8) | |
FEV1% predicted | 86.9 (15.1) | 88.3 (14.1) | |
PEF, L/min | 435.7 (8.3) | 452.9 (8.1) | |
PEF % predicted | 97.8 (21.4) | 100.5 (20.3) | |
Number of days/week with symptomsa | 0.5 (1.2) | 0.3 (0.6) | |
Number of nights/week with symptomsa | 0.3 (1.1) | 0.1 (0.6) | |
Rescue medication use, puffs/weeka | 1.2 (0.4) | 1.2 (0.4) | |
Rescue-free days/weekb | 6.6 (1.4) | 6.6 (1.2) | |
PEF >80%, days/weekb | 5.6 (1.9) | 5.5 (1.6) | |
Controlled asthmab, n (%) | 203 (98.5) | 212 (98.1) | |
Partly controlled asthmab, % | 2 (1.0) | 3 (1.4) | |
Uncontrolled asthmab, % | 1 (0.5) | 1 (0.5) |